Details

Autor(en) / Beteiligte

• O'Kell, Allison L
• Lytle, Katherine M
• Cohen, Todd A
• Wong, Lilian K
• Sandford, Emily
• Rafalko, Jill M
• Brandstetter, Gina
• DiMarzio, Lauren R
• Phelps-Dunn, Ashley
• Rosentel, Michelle C
• Warren, Chelsea D
• McCleary-Wheeler, Angela L
• Fiaux, Patrick C
• Marass, Francesco
• Marshall, Maggie A
• Ruiz-Perez, Carlos A
• Kruglyak, Kristina M
• Tynan, John A
• Hicks, Susan C
• Grosu, Daniel S
• Chibuk, Jason
• Chorny, Ilya
• Tsui, Dana W Y
• Flory, Andi

Titel

Clinical experience with next-generation sequencing-based liquid biopsy testing for cancer detection in dogs: a review of 1,500 consecutive clinical cases

Ist Teil von

• Journal of the American Veterinary Medical Association, 2023-06, Vol.261 (6), p.827

Ort / Verlag

United States

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• To review ordering patterns, positivity rates, and outcome data for a subset of consecutive samples submitted for a commercially available, blood-based multicancer early-detection liquid biopsy test for dogs using next-generation sequencing at 1 laboratory. 1,500 consecutively submitted blood samples from client-owned dogs with and without clinical suspicion and/or history of cancer for prospective liquid biopsy testing between December 28, 2021, and June 28, 2022. We performed a retrospective observational study, reviewing data from 1,500 consecutive clinical samples submitted for liquid biopsy testing. Outcome data were obtained via medical record review, direct communication with the referring clinic, and/or a patient outcome survey through October 16, 2022. Sixty-four percent (910/1,419) of reportable samples were submitted for cancer screening, 26% (366/1,419) for aid in diagnosis, and 10% (143/1,419) for other indications. The positivity rate was 25.4% (93/366) in aid-in-diagnosis patients and 4.5% (41/910) in screening patients. Outcome data were available for 33% (465/1,401) of patients, and outcomes were classifiable for 428 patients. The relative observed sensitivity was 61.5% (67/109) and specificity was 97.5% (311/319). The positive predictive value was 75.0% (21/28) for screening patients and 97.7% (43/44) for aid-in-diagnosis patients, and the time to diagnostic resolution following a positive result was < 2 weeks in most cases. Liquid biopsy using next-generation sequencing represents a novel tool for noninvasive detection of cancer in dogs. Real-world clinical performance meets or exceeds expectations established in the test's clinical validation study.